TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04770779
Drug: Mitapivat
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT06480110
Drug: Docetaxel + Ebastine
Normalized name: ebastine
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ebastine is administered once daily.
Study: NCT06480110
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel every three weeks
Study: NCT06496412
Drug: fecal microbiota transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take fecal microbiota capsules.
Study: NCT05672537
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg intravenous injection for 21d cycle
Study: NCT05672537
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
Study: NCT05672537
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 25mg/m2, D1\&D8, 21d cycle.
Study: NCT06685978
Drug: Xiang Ju Ru Pi Ning capsule
Normalized name: Ding xiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
Study: NCT06695598
Drug: CKD-383
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04942886
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
Study: NCT06403267
Drug: NoNO-42
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
Study: NCT04973293
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg, 4 cycles of treatment before surgery
Study: NCT04973293
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
Study: NCT05381636
Drug: Systemic intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
Study: NCT06517511
Drug: Selinexor Oral Tablet [Xpovio]
Normalized name: selinexor Oral Tablet [Xpovio]
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
Study: NCT06291727
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
Study: NCT06291727
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
Study: NCT04559139
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04559139
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05889741
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Study: NCT06496971
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An anti-angiogenic agent to block tumor growth
Study: NCT00002101
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002101
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05875610
Drug: Venlafaxine 75 MG
Normalized name: venlafaxine 75 MG
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine 75 mg extended release capsules for a 7-days duration
Study: NCT05875610
Drug: Gabapentin 400 mg
Normalized name: gabapentin 400 MG
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 400 mg capsules
Study: NCT05338450
Drug: Clemastine Fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
Study: NCT06367153
Drug: BI 1569912
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1569912
Study: NCT06367153
Drug: repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repaglinide
Study: NCT06367153
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam
Study: NCT06367153
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion
Study: NCT04829214
Drug: OTO-313
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection
Study: NCT05424315
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg Tab once daily
Study: NCT05424315
Drug: Glucose Tab
Normalized name: Glucose Tablets Orange Obsolete
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT05838885
Drug: rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Study: NCT05838885
Drug: rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Study: NCT04869124
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
Study: NCT05860296
Drug: SLC-391
Normalized name: SLC-391
DrugBank: SLC-391 (DB18814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLC-391 is an AXL inhibitor
Study: NCT05561140
Drug: Voxelotor Oral Tablet
Normalized name: voxelotor Oral Tablet
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Synthetic small molecule supplied as 500 mg tablets, administered Orally
Study: NCT06272058
Drug: Avenciguat (BI 685509)
Normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat (BI 685509)
Study: NCT05587998
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive IV dose of Morphine as stated in arm description.
Study: NCT05991466
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block.
Study: NCT04991454
Drug: 129Xe Hyperpolarized
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
Study: NCT06527937
Drug: DESF
Normalized name: Desferal
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DESF administered in the sublingual space.
Study: NCT06121284
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
Study: NCT04717908
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg once daily for 2 weeks then 200mg 3 times per week;
Study: NCT04717908
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1500 mg daily
Study: NCT04717908
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg daily
Study: NCT04717908
Drug: Cycloserine
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ≤50kg 500 mg daily, \>50kg 750mg daily;
Study: NCT04717908
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily;
Study: NCT05879432
Drug: LSALT Peptide
Normalized name: LSALT Peptide
DrugBank: LSALT Peptide (DB16472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
Study: NCT06644768
Drug: valemetostat tosylate
Normalized name: tazemetostat
DrugBank: Valemetostat (DB18314)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
Study: NCT06644768
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Study: NCT06003829
Drug: Sinsunatovir
Normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, to be spit out after tasting
Study: NCT06593665
Drug: Inrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
Study: NCT06593665
Drug: Intravenous Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
Study: NCT06679062
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
Study: NCT06290687
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)
Study: NCT06683924
Drug: Steroid (dexamethasone) Injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
Study: NCT06687551
Drug: Baricitinib (LY3009104) 4 mg
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day
Study: NCT06687551
Drug: filgotinib 200mg/day
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day
Study: NCT06687551
Drug: Tofacitinib 5 mg twice daily
Normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day
Study: NCT06687551
Drug: Upadacitinib 15 MG
Normalized name: upadacitinib 15 MG
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days
Study: NCT06687551
Drug: Baricitinib (LY3009104) 4 mg
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: use of JAK inhibitor at full dose until the end of the protocol
Study: NCT06687551
Drug: filgotinib 200mg/day
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: use of JAK inhibitor at full dose until the end of the protocol
Study: NCT06687551
Drug: Tofacitinib 5 mg twice daily
Normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: use of JAK inhibitor at full dose until the end of the protocol
Study: NCT06687551
Drug: Upadacitinib 15 MG
Normalized name: upadacitinib 15 MG
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: use of JAK inhibitor at full dose until the end of the protocol
Study: NCT06691802
Drug: Shu Fei Tie
Normalized name: Feiba
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
Study: NCT06690021
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
Study: NCT06192186
Drug: Adebrelimab combined with SOX regimen
Normalized name: Anacin Aspirin Regimen
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
Study: NCT06618664
Drug: SHR-8068
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-8068: injection, 50 mg/10 mL, intravenous infusion
Study: NCT06618664
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
Study: NCT06618664
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
Study: NCT06618664
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab: injection, 100 mg/10 mL, intravenous infusion
Study: NCT06627478
Drug: NKF-INS(G)
Normalized name: INS 316
DrugBank: INS 316 (DB05390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06694207
Drug: Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients
Study: NCT06695143
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 2% cream
Study: NCT06695962
Drug: Domperidone 10mg
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg per day for 21 days
Study: NCT06689358
Drug: 0.4 ml/kg of 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
Study: NCT06688188
Drug: 68Ga-JH12
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 148-222 MBq given intravenously.
Study: NCT04484363
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
Study: NCT04484363
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
Study: NCT06687993
Drug: Donepezil 2.5 mg
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg daily oral intake for 90 days
Study: NCT06687993
Drug: Donepezil 5 mg
Normalized name: donepezil 5 mg oral tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily oral intake for 90 days
Study: NCT06689514
Drug: Low dose Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID
Study: NCT06689514
Drug: High dose Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
Study: NCT06691061
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: UC patients treated with vedolizumab
Study: NCT06691061
Drug: Ustekinumab - Standard Dosage
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: UC patients treated with ustekinumab
Study: NCT06691412
Drug: Obeticholic Acid 5 mg
Normalized name: obeticholic acid 5 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
Study: NCT06688305
Drug: 68Ga-NI-FAPI
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
Study: NCT06687473
Drug: Bismuth-based susceptibility-guided treatment
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
Study: NCT05894564
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Study: NCT05206604
Drug: PF-07295324
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment
Study: NCT05206604
Drug: PF-07259955
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream